Analysis

Researcher in a medical lab
#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Mass spectrometry / NMR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing

Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #PCR #Pharmacogenomics #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Sequencing

Long-Read Sequencing Offers Path to More Accurate Drug Metabolism Profiles

Long-Read Sequencing Offers Path to More Accurate Drug Metabolism Profiles By Dr Jenny Ekholm In the complex drug discovery process, one of the looming questions for any new compound is how it will be metabolised in a human body. While there are several methods for evaluating this,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Lead discovery #RNA #Sequencing #System biology #Systems biology #Target validation

UX Design – Maximising the Value of Scientific Software in Life Science R&D

UX Design – Maximising the Value of Scientific Software in Life Science R&D By Dr Jennifer A. Cham & Katrina Costa Using scientific software can be frustrating and time-consuming, resulting in less productive research. This article aims to demonstrate that User Experience (UX) Design – an evidence-based design… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Imaging #Immunology #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Precision medicine #Regulatory #RNA #Stem cells #Therapeutics

Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy

Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #PCR #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format

Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format By Dr John Comley There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D cell culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Lead discovery #Molecular medicine #Preclinical #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Discoverome – Creative Destruction of Barriers for Faster to Patient Medicines R&D

The Discoverome – Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly… Read More

#Archive

#Academic #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target

Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Genetics #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Organic chemistry #Patent Law #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

A Strategic Vision For 21st Century Drug Discovery

A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Organic chemistry #Orphan drugs #Pathology #Pharmacogenomics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Business #Cell culture #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Is The Cloud Enabling Bioinformatics to Become the Biology Solutions Domain?

By Dr Paul Denny-Gouldson For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Lead discovery #Medicinal chemistry #Precision medicine #Preclinical #RNA #Target validation #Toxicology

Why Adopting AI is Essential for a Sustainable Pharma Industry

Why Adopting AI is Essential for a Sustainable Pharma Industry By Professor Jackie Hunter Advancements in technology, and in particular, developments in artificial intelligence (AI) are revolutionising the way that we live our lives. Up to now, we have used it to help us find the quickest… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Genetics #High Content Screening #High throughput screening #Imaging #Immunology #Medicinal chemistry #Microfluidics #Molecular medicine #Oncology #Organic chemistry #Pathology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Cellular Imaging – Advances and Considerations for High-Content Screening

3D Cellular Imaging – Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

I Robot. I, The Future – Robotics Within and Beyond The Lab

I Robot. I, The Future – Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation… Read More

#Archive

CRISPR gene editing
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs

CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions… Read More

#Archive

Gene therapy
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Regenerative Medicine #Regulatory #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Cell Therapy & Gene Therapy – The emerging fourth pillar of healthcare systems

Cell Therapy & Gene Therapy – The emerging fourth pillar of healthcare systems By Keith Thompson As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar… Read More

#Archive